Table 2.

Characteristics of Study Cohort

Characteristic401 to 500 g501 to 600 g601 to 700 g701 to 800 g801 to 900 g901 to 1000 gTotal
Cohort18 (1)119 (8)271 (18)324 (21)403 (26)392 (26)1527 (100)
Postneonatal deaths0 (0)2 (2)12 (4)6 (2)11 (3)16 (4)47 (3)
Evaluated15 (83)94 (80)208 (80)237 (75)290 (74)307 (82)1151 (78)
Gestational age25.3 ± 2.224.7 ± 1.925.0 ± 1.826.0 ± 1.826.8 ± 1.927.6 ± 2.026.3 ± 2
Antenatal steroids9 (60)37 (39)67 (33)94 (40)99 (34)132 (43)438 (38)
Preeclampsia8 (53)28 (30)32 (16)41 (17)57 (20)73 (24)239 (21)
Surfactant9 (60)67 (71)160 (77)173 (73)207 (71)193 (63)809 (70)
Oxygen (36 wk)8 (53)48 (51)102 (49)107 (45)103 (36)91 (30)459 (40)
Oxygen (d)72 ± 4577 ± 3373 ± 3563 ± 3749 ± 3440 ± 3556 ± 38
Postnatal steroids8 (53)64 (68)123 (59)119 (50)111 (38)87 (28)512 (44)
Grade 3–4
IVH/PVL
1 (7)15 (16)47 (23)51 (22)51 (18)47 (15)212 (18)
Retinopathy of
prematurity
(all grades)
12 (80)84 (90)167/202
(83)
177/223
(79)
170/267
(64)
141/281
(50)
751/1081
(70)
SGA status 11 (73)32 (34)31 (15)38 (16)44 (15)54 (18)210 (18)
Male gender6 (40)33 (35)82 (39)115 (49)146 (50)158 (51)540 (47)
Hospital days
(median/range)
132
(87–188)
119
(76–552)
109
(56–507)
99
(47–651)
84
(17–487)
73
(13–1076)
92
(13–1076)
Multiple births3 (20)14 (15)30 (14)47 (20)73 (25)55 (18)222 (19)
  • Data expressed as n (%) or mean ± SD.

  • * Less than tenth percentile for weight using the growth curves by Alexander et al.15